FDA sets July PCAC review for 7 compounded peptides
The FDA has scheduled a July 23-24, 2026 PCAC meeting to consider adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and Emideltide to the 503A bulks list.
May 9, 2026 · 3 min read
The FDA has formally scheduled its Pharmacy Compounding Advisory Committee to meet on July 23-24, 2026, to evaluate seven peptides — including BPC-157, TB-500, and MOTS-c — for possible addition to the Section 503A Bulk Drug Substances List. The docket, FDA-2026-N-2979, is open for public comments through July 22, with comments submitted by July 9 distributed to committee members in advance. If PCAC recommends inclusion and FDA completes rulemaking, licensed compounding pharmacies could legally prepare these peptides for the first time.
What happened
On April 16, 2026, the FDA published notice of the PCAC meeting alongside the opening of a public comment docket. The session splits across two days: July 23 covers BPC-157-related substances, TB-500-related substances, KPV-related substances, and MOTS-c-related substances; July 24 covers Emideltide (DSIP), Semax, and Epitalon. Each peptide will be assessed on whether available evidence supports its safety and clinical use in compounded form.
This announcement follows a separate April 2026 regulatory action in which HHS Secretary Robert F. Kennedy Jr. confirmed the removal of 12 peptides — including several of the same compounds — from the FDA's Category 2 "do not compound" list. Those removals took effect on April 23, 2026, meaning standard 503A pharmacy regulations now apply while the PCAC process plays out. The July meeting is the next formal procedural step toward potential 503A inclusion.
The stakes are meaningful. The 503A Bulk Drug Substances List is how compounding pharmacies obtain legal authorization to prepare substances that are not commercially available approved drugs. Peptides not on the list operate in a regulatory grey zone even after the Category 2 removals.
Why it matters
Until earlier this year, BPC-157 and TB-500 sat on the FDA's Category 2 list — substances flagged as presenting potential safety risks that should not be compounded. That designation effectively closed off legal routes for U.S. pharmacies. The April removals opened the door; a positive PCAC recommendation in July could widen it considerably.
For practitioners and patients, the distinction matters. Compounding pharmacies operating under 503A must use licensed dispensing, physician prescriptions, and quality-controlled manufacturing — a very different risk profile from research-chemical suppliers. If BPC-157 or TB-500 reach 503A Category 1, the supply chain for prescribed use shifts from unregulated online vendors to licensed pharmacies.
The July meeting is not the finish line. A PCAC recommendation is advisory, not binding. Even a positive recommendation triggers notice-and-comment rulemaking before any formal rule change. That process can take months to years. For context on where BPC-157 stood before these developments, see our earlier coverage of the 503A compounding history.
What to watch
- Whether PCAC votes to recommend any of the seven peptides for 503A inclusion — results are expected shortly after the July 24 session
- The quality and volume of public comments submitted to docket FDA-2026-N-2979 by the July 9 pre-meeting deadline
- Whether FDA proceeds to formal rulemaking after a positive recommendation, and the timeline it sets
- Any manufacturer or compounder announcements about preparing to supply these peptides under 503A if rules change
- MOTS-c and Epitalon separately, as both have thin human data — the evidentiary bar for their inclusion may be higher than for BPC-157 or TB-500
Sources
Sources